^
    Apply
    Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers (NCT00788684)
    Phase 1
    AbbVie
    Completed
    Last update posted :
    02/20/2025
    Initiation :
    07/21/2009
    Primary completion :
    02/07/2025
    Completion :
    02/07/2025
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • navitoclax (ABT 263)
    Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors (NCT02079740)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    03/26/2014
    Primary completion :
    12/01/2022
    Completion :
    03/07/2025
    KRAS • NRAS • BCL2L2
    |
    KRAS mutation • NRAS mutation
    |
    Mekinist (trametinib) • navitoclax (ABT 263) • omipalisib (GSK2126458)
    Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome (22P.205) (NCT05564650)
    Phase 1/2
    Thomas Jefferson University
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    01/12/2023
    Primary completion :
    04/10/2026
    Completion :
    04/10/2026
    BCL2
    |
    BCL2 expression
    |
    Venclexta (venetoclax) • azacitidine • decitabine • navitoclax (ABT 263)
    Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors (NCT02143401)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/22/2024
    Initiation :
    11/07/2014
    Primary completion :
    11/30/2022
    Completion :
    05/20/2025
    MCL1 • AFP • CASP3
    |
    MCL1 expression
    |
    sorafenib • navitoclax (ABT 263)
    Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma (NCI-2013-02103) (NCT01989585)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/16/2024
    Initiation :
    03/24/2014
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    PTEN • BCL2
    |
    BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • navitoclax (ABT 263)
    Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma (NCT05864742)
    Phase 2
    Peter MacCallum Cancer Centre, Australia
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    09/07/2023
    Primary completion :
    06/01/2026
    Completion :
    06/01/2029
    BCL2 • BCL2L2 • SMARCA2
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • navitoclax (ABT 263)
    Combination of Olaparib and Navitoclax in Women With HGSC and TNBC (Exactis-03) (NCT05358639)
    Phase 1
    Sunnybrook Health Sciences Centre
    Recruiting
    Last update posted :
    07/07/2023
    Initiation :
    11/09/2022
    Primary completion :
    04/28/2024
    Completion :
    04/28/2025
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • PALB2 mutation
    |
    Lynparza (olaparib) • navitoclax (ABT 263)
    A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL (ITALLI001) (NCT05054465)
    Phase 1b
    Israeli Medical Association
    Not yet recruiting
    Last update posted :
    09/23/2021
    Initiation :
    10/01/2021
    Primary completion :
    08/01/2025
    Completion :
    08/01/2026
    BCL2
    |
    Venclexta (venetoclax) • navitoclax (ABT 263)
    A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer (MONAVI-1) (NCT02591095)
    Phase 2
    Centre Francois Baclesse
    Completed
    Last update posted :
    03/19/2019
    Initiation :
    01/01/2016
    Primary completion :
    04/01/2017
    Completion :
    03/01/2019
    BCL2L11
    |
    navitoclax (ABT 263)
    A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies (NCT00445198)
    Phase 1/2
    AbbVie (prior sponsor, Abbott)
    Completed
    Last update posted :
    06/06/2018
    Initiation :
    04/01/2007
    Primary completion :
    12/01/2010
    Completion :
    12/01/2010
    BCL2
    |
    navitoclax (ABT 263)
    A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) (NCT01087151)
    Phase 2
    Genentech, Inc.
    Completed
    Last update posted :
    11/02/2016
    Initiation :
    08/01/2010
    Primary completion :
    06/01/2012
    Completion :
    06/01/2012
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • navitoclax (ABT 263)